ADC Therapeutics is a commercial-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for the treatment of hematologic cancers and solid tumors. Its lead product Zynlonta (loncastuximab tesirine) is the first CD19-targeted ADC approved for relapsed/refractory diffuse large B-cell lymphoma. The company is advancing a pipeline of next-generation ADCs targeting both hematologic malignancies and selected solid tumors.
Company Info
Upcoming Milestones & Key Dates
FDA Oncologic Drugs Advisory Committee meeting on Zynlonta confirmatory data interpretation
Q2 2026 earnings and Zynlonta commercial update
Clinical Development Pipeline
Recent News
ADC Therapeutics' confirmatory Phase 3 data for Zynlonta (loncastuximab tesirine) in diffuse large B-cell lymphoma was complicated by elevated death rates in the experimental arm, raising new doubts about the drug's risk-benefit profile.
Leadership Team
Careers & Job Openings